Bicoastal venture firm New Enterprise Associates owns 75.2 percent of GlycoMimetics Inc., making NEA by far the biggest beneficiary of the Gaithersburg biotech's planned initial public offering.
The company revealed NEA's outsized ownership in its IPO paperwork, filed on Friday. It is not yet clear whether the firm, which has a major office in Chevy Chase, plans to sell some of its 26.7 million shares in the offering.